Curing Cancer: Stocks To Give Your Portfolio A Boost

Curing Cancer: Stocks To Give Your Portfolio A Boost

Research  these Stocks on Kapitall’s Playground Now

research now

Cancer drugmaker stocks present an interesting opportunity to investors. Although there is no guarantee a company with a drug in the pipeline will be approved let alone popular, (two reasons why the biotech industry is wrought with risk) getting in early can mean big returns if the company releases a blockbuster drug. (STAY AHEAD OF THE CURVE: Follow Kapitall on Twitter)

These stocks can quickly rise in value if they pass certain goals in testing, reach approval, or reach commercial success. They can also rise in value when the companies present their research at the American Society of Clinical Oncology (ASCO), which holds their annual meeting in June.  These presentations can be real game changers for the world of medicine, and for stock values.

Business Section: Investing Ideas

The society will be posting research abstracts for the meeting on its website May 16th. Until then, there are seven companies with stocks expected to present at this year's ASCO meeting.

TheStreet has compiled some need-to-know information on these companies for investors. Do you agree it would be wise to keep these names on your radar?


Interactive Chart: Use the Compar-O-Matic to compare analyst ratings for the stocks mentioned below:


“1. Celldex Therapeutics (CLDX, Earnings, Analysts, Financials): Not much is known, but the company will discuss Phase IIb study of CDX-011 in refractory breast cancer. According to TheStreet, "Celldex enrolled 120 patients with advanced breast cancer that over-expresses a protein known as GPNMB (confirmed by an independent test). The patients, all of whom no longer respond to currently approved treatments, are then randomized to receive either CDX-011 or physician's choice of treatment. The primary endpoint of the study is overall response rate."


“2. Arqule (ARQL, Earnings, Analysts, Financials): The company will present on A phase II study of tivantinib (ARQ-197) in second-line liver cancer. "Top-line data from this phase II study were released in January. Liver cancer patients who progressed after first-line therapy were randomized 2:1 to receive tivantinib or a placebo. The study met its primary endpoint with tivantinib demonstrating a 56% improvement in time to tumor regrowth compared to the placebo."


“3. Johnson & Johnson (JNJ, Earnings, Analysts, Financials): At ASCO, JNJ will present Phase III study of Zytiga in "pre-chemo" prostate cancer patients. "At this point, the Zytiga study is the biggest attention grabber at ASCO from a Wall Street perspective because the results have far-reaching impact not only on J&J but prostate cancer drug competitors Medivation (MDVN) and Dendreon (DNDN).


“4. Ariad Pharmaceuticals (ARIA, Earnings, Analysts, Financials): Will present on six-month, follow-up data from the pivotal phase III study of ponatinib in chronic myelogenous leukemia. "Results from the first three months of the ponatinib PACE study were presented last December… Investors will be looking for six-month response rates to be higher than what was seen last December."


“5. Aveo Pharmaceuticals (AVEO, Earnings, Analysts, Financials): According to TheStreet, Aveo will give a full presentation of results from the phase III study of tivozanib in kidney cancer. "Top-line results from the kidney cancer study were announced in early January with tivozanib demonstrating a progression-free survival of 11.9 months compared to 9.1 months for Nexavar."


“6. Array BioPharma (ARRY, Earnings, Analysts, Financials): Presenting on Selumetinib in second-line non-small cell lung cancer. Last September's "survival trend favoring selumetinib wasn't statistically significant but full details on the drug's efficacy, including PFS and response rate endpoints, will be presented at ASCO."


“7. Oncothyreon (ONTY, Earnings, Analysts, Financials): Phase II studies of PX-866 in solid tumors. "Phase I trials showed PX-866 to be well tolerated with some evidence of anti-cancer activity. Oncothyreon is conducting phase II studies of PX-866 in combination with other drugs in non-small cell lung cancer, glioblastoma, prostate cancer, colon cancer and head-and-neck cancer."



(Rebecca Lipman does not own shares in any of the companies mentioned above. Data sourced from TheStreet.)


Use Kapitall's Tools: Looking for ways to analyze this list?

Use this article snapshot as a launch pad (click here for help): Simply click on the links, and use Kapitall's tab navigation to browse through the data…


Analyze These Ideas: Getting Started

Dig Deeper: Access Company Snapshots, Charts, Filings

New to Kapitall?

1. New to the site? Click here to register for a free account, and gain access to more tools and data
2. Looking for more investing ideas like this? Click here to sign up for your free copy of Kapitall Weekly
3. Follow us on SeekingAlpha, Motley Fool, Nasdaq and Twitter


2 responses to “Curing Cancer: Stocks To Give Your Portfolio A Boost”

  1. Buy Xeloda says:

    This post is very encouraging and helpful for me. Thanks for sharing your ideas with us.

  2. Jeff says:

    Thanks for the tips

    I've heard of Arqule before and nkow of their studies of second-line Liver Cancer – I'll look into the rest – thanks again!

    An Avid Investor

Leave a Reply

Your email address will not be published. Required fields are marked *

  • See Most Recent Articles